|
|
|
|
CancerEducation: Presentations - Multiple Myeloma Update From the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
|
|
Multiple myeloma is a hematologic malignancy that affects tens of thousands of people annually. For decades, there had been limited therapeutic advances for myeloma patients as the understanding of this disease slowly increased. In more recent years, because of the discovery of some of the molecular pathways involved in myeloma, new therapies have been successful in clinical studies for treating both relapsed/refractory diseases in myeloma patients as well as treating newly diagnosed patients. In addition, increased attention and study has been focused on improving the efficacy and tolerability of transplantation. |
|
|
|
This activity has been designed to meet the educational needs of healthcare professionals involved in the management of patients with multiple myeloma. |
|
|
|
Upon completion of this activity, the participants will be able to - Review clinical advancements in the treatment of patients with newly diagnosed multiple myeloma.
- Describe the role of novel targeted therapies for treating patients with relapsed and refractory multiple myeloma.
- Review side effect profiles of new myeloma therapies.
|
|
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), AOI Communications, L.P. (AOIC), and the Multiple Myeloma Research Foundation (MMRF). PIM is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
|
Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
- Carol Ann Huff, MD
Johns Hopkins University Hospital
Baltimore, MD - Ravi Vij, MD
Washington University School of Medicine
St. Louis, MO
|
|
|
|
Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity
Name of Faculty or Presenter |
Reported Financial Relationship |
 | |
Carol Ann Huff, MD |
Consulting Fees: Celgene |
| |
Ravi Vij, MD |
Consulting Fees: Celgene, Millennium and Merck
Non-CME Services: Celgene, Millennium, Novartis, and Ortho Biotech |
| |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity
Name of Planner or Manager |
Reported Financial Relationship |
| |
Thomas J. Burke (AOIC) |
No financial interest/relationships with financial interests relating to the topic of this activity
|
| |
Mary Dominiecki, PhD (AOIC)
|
No financial interest/relationships with financial interests relating to the topic of this activity
|
| |
Michelle DiMichele (AOIC)
|
No financial interest/relationships with financial interests relating to the topic of this activity
|
| |
Anne Quinn Young, MPH (MMRF) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Linda Graham, RN, BSN, BA (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Jan Hixon, RN, BSN, MA (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Trace Hutchison, PharmD (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Julia Kirkwood, RN, BSN (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Jan Schultz, RN, MSN, CCMEP (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
|
|
|
|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), the Multiple Myeloma Research Foundation, AOI Communications, L.P., Celgene Corporation, Millennium Pharmaceuticals, Inc., Centocor Ortho Biotech Inc., Novartis Pharmaceuticals Corporation, and Merck & Co., Inc., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, the Multiple Myeloma Research Foundation, AOI Communications, L.P., Celgene Corporation, Millennium Pharmaceuticals, Inc., Centocor Ortho Biotech Inc., Novartis Pharmaceuticals Corporation, and Merck & Co., Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. |
|
|
|
There are no fees for participating and receiving CME credit for this activity. During the period from June 3, 2009 through June 30, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) Postgraduate Institute for Medicine will mail your certification of completion.A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks. |
|
|
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. |
Click to continue
|
|
|
|
|
|
|
Carol Ann Huff, MD
